We have recently reported that ligation of the CD44 cell surface antigen with A3D8 monoclonal antibody (mAb) triggers incomplete differentiation and apoptosis of the acute promyelocytic leukemia (APL)-derived NB4 cells. The present study characterizes the mechanisms underlying the apoptotic effect of A3D8 in NB4 cells. We show that A3D8 induces activation of both initiator caspase-8 and -9 and effector caspase-3 and -7 but only inhibition of caspase-3/7 and caspase-8 reduces A3D8-induced apoptosis. Moreover, A3D8 induces mitochondrial alterations (decrease in mitochondrial membrane potential DW m and cytochrome c release), which are reduced by caspase-8 inhibitor, suggesting that caspase-8 is primarily involved in A3D8-induced apoptosis of NB4 cells. However, the apoptotic process is independent of TNF-family death receptor signalling. Interestingly, the general serine protease inhibitor 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) decreases A3D8-induced apoptosis and when combined with general caspase inhibitor displays an additive effect resulting in complete prevention of apoptosis. These results suggest that both caspase-dependent and serine protease-dependent pathways contribute to A3D8-induced apoptosis. Finally, A3D8 induces apoptosis in all-trans-retinoic acid-resistant NB4-derived cells and in APL primary blasts, characterizing the A3D8 anti-CD44 mAb as a novel class of apoptosis-inducing agent in APL.
Introduction
Acute promyelocytic leukemia (APL or AML-M3) represents a unique model for cancer research in terms of its biological and clinical features. 1 Indeed, this leukemic subtype displays the specific chromosomal translocation t(15;17) encoding the PMLRARa fusion oncoprotein. 2, 3 In addition, the survival of APL patients has been highly improved in recent years, by using a specific therapy combining a differentiation-inducing molecule, all-trans-retinoic acid (ATRA) and chemotherapy. 4 However, since the disease may become resistant to this treatment and relapse, 5 it is necessary to find out complementary treatments for stabilizing the clinical remission. Arsenic trioxide (As 2 O 3 ), which triggers both apoptosis and partial differentiation in APL cells, in vitro and in vivo, 6, 7 has been reported to induce durable remission in relapsed APL patients. 8, 9 However, As 2 O 3 provokes deleterious side effects, including lethal hepatic damage, cardiac dysfunctions and sudden death, that restrict its clinical use. 10 Interestingly, we have recently reported that ligation of the CD44 cell surface antigen with the A3D8 monoclonal antibody (mAb) induces incomplete differentiation and massive apoptosis in the APL-derived NB4 cell line. 11 The induction of apoptosis is specific to both the NB4 cell line and the A3D8 mAb. Indeed, A3D8 triggers only little apoptosis in other myeloid leukemia cell lines (THP-1 and HL60), and other anti-CD44 mAbs affecting AML cells (like H90) do not induce any significant apoptosis in NB4 cells. 11 Since the dual effect of A3D8 (incomplete differentiation and apoptosis) is similar to the one exerted by As 2 O 3 in NB4 cells, 7 A3D8 may be as efficient as As 2 O 3 , but less toxic, for eradicating APL blasts in vivo. To further investigate this possibility, it is necessary to elucidate the mechanisms of A3D8-induced apoptosis in NB4 cells.
In the present study, we have characterized the apoptotic pathways mediated by A3D8 in NB4 cells. We show that A3D8-induced apoptosis is mediated by a pathway dependent on caspases, a family of cysteine proteases, playing a central role in apoptosis and that caspase-8 is primarily involved in the process but independently of death receptors. In addition, we show that serine proteases contribute to A3D8-induced apoptosis. Finally, A3D8 can induce apoptosis in ATRA-resistant NB4 cells and in primary As 2 O 3 -resistant APL blasts, suggesting that A3D8 may be a novel and alternative apoptosis-inducing therapeutic agent in APL.
Materials and methods

Reagents
ATRA and the mAb directed to human CD44 (clone A3D8) were purchased from Sigma Aldrich (Saint-Quentin-Fallavier, France). As 2 O 3 was generously given by Dr H de Thé (Hô pital SaintLouis, Paris, France). The primary antibodies used in Western blot analysis were as follows: anti-cytochrome c, anti-poly-ADPribose polymerase (PARP), anti-caspase-3 and anti-caspase-7 from BD PharMingen (Le Pont de Claix, France), anti-caspase-8 from Alexis (San Diego, CA, USA), anti-caspase-9 from Cayman (Ann Arbor, MI, USA) and anti-actin from Sigma Aldrich. The caspase inhibitors Z-VAD-fmk (general caspase inhibitor), Z-DEVD-fmk (caspase-3/7 inhibitor), Z-IETD-fmk (caspase-8 inhibitor) and Z-LEHD-fmk (caspase-9 inhibitor) were all purchased from Enzyme Systems Products (Livermore, CA, USA). 3,3 0 -dihexyloxacarbocyanine iodide (DiOC6(3)) was from Calbiochem (La Jolla, CA, USA). Serine protease inhibitors (4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), TLCK (N-a-tosyl-L-lysine chloromethyl ketone), TPCK (N-a-tosyl-L-phenylalanine chloromethyl ketone)), calpain inhibitors (calpeptin, ALLM and PD150606), general cystein protease inhibitor EST (E-64-d) and proteasome inhibitor (MG132) were from Calbiochem. The Fas-neutralizing mAb clone ZB4 from MBL (Watertown, MA, USA), the human TNF-R1 mAb clone 16803 from RD System (Minneapolis, MN, USA) and the mAbs HS101 and HS201 (anti-TRAIL-R1 and anti-TRAIL-R2, respectively) from Alexis were used for blocking experiments.
Cell culture and CD44 ligation
The human myeloid leukemia cell line NB4 12 and the NB4-derived line NB4-LR2 13 (kindly provided by M Lanotte) were cultured by initially seeding 2 Â 10 5 cells/ml in RPMI-1640 medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS), 50 mg/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml neomycin (GIBCO-BRL) and 2 mM L-glutamine (GIBCO-BRL), in a humidified atmosphere of 5% CO 2 at 371C. Fresh blasts from two cases of de novo APL patients, obtained with informed consent, were separated by centrifugation on Ficoll's solution as described previously 14 and cultured in the presence of RPMI-1640 containing 10% FCS. Cells seeded at 2 Â 10 5 cells/ml in the media described above were treated with mAb A3D8 (IgG1) at various concentrations (0.5-20 mg/ml). Negative controls were incubated with the same concentrations of murine IgG1 (Coulter-Immunotech, Marseille-Luminy, France).
Cell viability analysis, apoptosis assays and DNA fragmentation analysis
In total, 2 Â 10 5 cells/ml were treated with various concentrations of A3D8 and, at the appropriate time, viable cells were counted every 24 h for 3 days using the Trypan blue dye exclusion assay. Morphology was evaluated by light microscopy of May-Grü nwald-Giemsa-stained cells. The percentage of apoptotic cells was determined by staining cells with a mixture of ethidium bromide (EB) and acridine orange (AO) as described previously. 15 Apoptosis was also analyzed by Annexin-V/ propidium iodide (PI) staining with a commercially available kit (BD PharMingen) as recommended by the manufacturer. Briefly, 1 Â 10 5 cells were washed in cold phosphate-buffered saline (PBS) and incubated in binding buffer containing fluorescein isothiocyanate-labeled Annexin-V and PI for 15 min at room temperature in the dark. Samples were then analyzed by flow cytometry with a FACSCalibur (BectonDickinson). DNA fragmentation was analyzed as described previously. 16 
Determination of mitochondrial transmembrane potential (DC m )
Variations of the DC m were determined by a previously described procedure. 17 Briefly, samples of 1 Â 10 6 cells were washed twice in PBS and incubated with 30 nM DiOC6(3) for 10 min at 371C. Cell fluorescence was then analyzed by using the FACSCalibur cytometer (FL-1 channel).
Preparation of cytosol for measurement of cytochrome c
To isolate the cytosol, we adapted a previously described method using a digitonine-based subcellular fractionation. 18 Briefly, 1 Â 10 6 cells were centrifuged, washed twice in PBS and incubated with a lysis buffer (250 mM sucrose, 70 mM KCl, 137 mM NaCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 (pH 7.2), 100 mM PMSF, 10 mg/ml leupeptin, 2 mg/ml aprotinin, 200 mg/ml digitonin) for 5 min on ice. After centrifugation at 1000 g for 5 min at 41C, the supernatant (cytosolic fraction) was removed and stored at À201C.
Western blot analysis
In total, 5 Â 10 6 cells were washed in PBS, lysed with 300 ml buffer containing 20 mM Tris-HCl (pH 7.0), 0.5% SDS and 1% benzonase (Sigma Aldrich) and then inactivated at 1001C for 3 min. Protein lysates were separated by 8 or 12% SDSpolyacrylamide gel electrophoresis (SDS-PAGE), blotted onto PolyScreen membranes (NEN, Paris, France) and processed for Western blot analysis as described previously. 19 After incubation of membranes with primary antibodies and secondary antimouse or anti-rabbit antibody conjugated with horseradish peroxidase, the protein bands were detected as described in the ECL protocol (NEN) using Reflection autoradiography film.
Statistical analysis
Data are expressed as means7s.d. of three independent experiments and statistically analyzed using Student's t-test. Values of Po0.05 were considered significant.
Results
A3D8 induces apoptosis in NB4 cells
As reported previously, 11, 20 CD44 ligation with the A3D8 anti-CD44 mAb, inhibited the proliferation of NB4 cells (not shown) and, from day 2, it induced apoptosis in a dose-and timedependent manner ( Figure 1a ). Based on the data, we used A3D8 at the concentration of 2 mg/ml inducing 30% apoptosis at day 3, for the subsequent analyses. May-Grü nwald-Giemsa staining confirmed that A3D8-treated NB4 cells displayed apoptosis-typical cytological features, including cellular shrinkage and chromatin condensation (data not shown). Apoptosis was confirmed by DNA-laddering fragmentation that appeared at day 3 ( Figure 1b) . Furthermore, annexin-V/PI double staining showed that at day 2 after A3D8 treatment, annexin-V þ /PI 
A3D8 induces caspase activation in NB4 cells
Most apoptosis pathways depend on the activation of caspases and distinct caspases are involved according to cell type and apoptosis inducer. 21, 22 To investigate the involvement of caspases in A3D8-induced apoptosis, we examined whether PARP, a substrate of caspases, was cleaved in A3D8-treated NB4 cells. Using Western blot analysis, we detected a 85 kDa cleavage product of PARP in NB4 cells at day 3 after A3D8 treatment ( Figure 2a ). Since PARP cleavage is mainly due to effector caspase-3 and -7, we assessed whether these caspases were activated in A3D8-treated NB4 cells. We detected at day 3 the active cleaved form of both caspase-3 and -7 in A3D8-treated cells. We then investigated whether the initiator caspase-8 and -9 were activated in the course of A3D8-induced apoptosis. As shown in Figure 2a , exposure to A3D8 resulted, at day 3, in the processing of caspase-8 into two fragments and in the cleavage of caspase-9 into two fragments. As described previously, 23 As 2 O 3 also induced a clear cleavage of caspase-3 and -8 in NB4 cells. In contrast, cleavage of caspase-7 and -9 was very minimal in As 2 O 3 -treated NB4 cells. Taken together, these results show that both the initiator caspase-8 and -9 and CD44-induced apoptosis in APL E Maquarre et al the effector caspase-3 and -7 were simultaneously activated in NB4 cells at day 3 after A3D8 treatment.
Caspase-3 and -8 inhibitors reduce A3D8-induced apoptosis
To determine whether activated caspases are involved in A3D8-induced apoptosis, NB4 cells were treated with 2 mg/ml of A3D8 in the presence or absence of several caspase inhibitors. As shown in Figure 2b , the pancaspase inhibitor Z-VAD-fmk, significantly decreased by 50% the percentage of apoptotic cells. The specific inhibitor of effector caspase-3/7 (Z-DEVDfmk) also reduced by half the extent of A3D8-induced apoptosis. These results strongly suggest that caspases participate in the execution of A3D8-induced apoptosis in NB4 cells, although not exclusively. As both initiator caspase-8 and -9 are activated in a similar time-dependent manner (Figure 2a ) during A3D8-induced apoptosis, it is difficult to distinguish their respective role in the process. To delineate their relative contribution in mediating A3D8-induced apoptosis, we examined the effects of specific inhibition of caspase-8 with the inhibitor Z-IETD-fmk or of caspase-9 with the inhibitor Z-LEHD-fmk. As shown in Figure 2b , Z-IETD-fmk reduced by half the number of apoptotic NB4 cells as efficiently as Z-DEVD-fmk. In contrast, Z-LEHDfmk had no effect. These results argue that caspase-8 activation, rather than caspase-9 activation, mediates A3D8-induced apoptosis of NB4 cells.
A3D8 induces loss of DC m and cytochrome c release in NB4 cells that are reduced by caspase-8 inhibitor
The activation of caspases is known to correlate with changes in DC m in the case of As 2 O 3 -induced apoptosis of NB4 cells. 23, 24 Therefore, the A3D8-induced variations in mitochondrial DC m were examined by measuring the uptake of DiOC6(3), a lipophilic fluorochrome, in A3D8-treated NB4 cells. The percentage of NB4 cells with a low DiOC6(3) staining began to increase at day 2 and was strongly increased at day 3 following the A3D8 addition, indicating a fall in the DC m ( Figure 3a) . As predicted from the loss in DC m , a release of mitochondrial cytochrome c into the cytosol was also observed in A3D8-treated NB4 cells at day 3 of treatment ( Figure 3b ). Both DC m loss and cytochrome c release were significantly reduced by the addition of the general Z-VAD-fmk, and of the caspase-8 inhibitor Z-IETD-fmk (Figure 3a and b) . These results indicate that A3D8 induces in the course of apoptosis alterations of mitochondrial membrane that are dependent on caspase-8 acting upstream of mitochondria. 
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Apoptosis induced by A3D8 is Fas-, TNF-R1-and TRAIL-DR4/DR5 independent
Since caspase-8 is activated and involved in A3D8-induced apoptosis, we investigated whether A3D8-induced apoptosis is mediated by TNF-family death receptors. 25 As shown in Figure 4 , the addition of the Fas-antagonistic antibody (ZB4), the TNF-R1-blocking antibody, or the TRAIL-R1-and TRAIL-R2-neutralizing antibodies had no effect on A3D8-induced apoptosis of NB4 cells. The inhibitory activity of the TNF-R1-blocking mAb was verified by its capacity to prevent TNFa-induced apoptosis in NB4 cells (Figure 4) . These results suggest that A3D8-induced apoptosis in NB4 cells is not mediated by the Fas, TNF-R1 or TRAIL receptors pathways.
Inhibitors of serine protease reduce apoptosis in A3D8-treated NB4 cells
Although activation of caspases and cleavage of their substrates are important for the execution of apoptosis, recent studies have indicated that proteases other than caspases (including cathepsins, calpains, and serine proteases) have roles in mediating and promoting apoptosis. 26, 27 Here, we found that the pancaspase inhibitor Z-VAD-fmk only partially reduced A3D8-induced apoptosis, even when it was used at high concentrations of 50 mM (Figure 2b ) or 100 mM (Table 1 ). This suggests that noncaspase proteases could play a role in apoptosis upon A3D8 treatment. To investigate this possibility, we have analyzed the effects of different protease inhibitors on A3D8-induced (a) Caspase activation in NB4 cells treated with A3D8. NB4 cells were cultured for 1, 2 and 3 days with 2 mg/ml A3D8 or IgG1 (control). Total cell proteins were analyzed by Western blotting with anti-PARP, anti-caspase-3, anti-caspase-7, anti-caspase-8 and anti-caspase-9 antibodies. For loading controls, membranes were stripped and reprobed for actin. NB4 cells treated with 5 mM As 2 O 3 for 24 h were used as control. The asterisks indicate additional nonspecific bands detected with anti-caspase-9 antibody. (b) Effect of caspase inhibitors on A3D8-induced apoptosis. NB4 cells were exposed to A3D8 (2 mg/ml) for 3 days in the absence or presence of the following inhibitors: pancaspase inhibitor Z-VAD-fmk (50 mM); and inhibitor of caspase-3/7 Z-DEVD-fmk (100 mM); inhibitor of caspase-9 Z-LEHD-fmk (10 mM); inhibitor of caspase-8 Z-IETD-fmk (100 mM). CD44-induced apoptosis in APL E Maquarre et al apoptosis. As summarized in Table 1 , no protection was observed with the calpain inhibitors (calpeptin, ALLM and PD150606), the cathepsin inhibitor EST, the proteasome inhibitor MG132 and the chymotrypsin-like serine protease inhibitor TPCK. In contrast, both the general serine protease inhibitor AEBSF and the trypsin-like serine protease inhibitor TLCK significantly decreased A3D8-induced apoptosis. The inhibiting effects of AEBSF and TLCK increased with increasing concentrations (shown for AEBSF in Figure 5 ) but we could not use concentrations higher than 100 mM because of intrinsic toxicity of both inhibitors. More importantly, Z-VAD-fmk together with AEBSF clearly displayed an additive effect. As shown in Figure 5 , the combination of 50 mM Z-VAD-fmk with 100 mM AEBSF significantly abrogated A3D8-induced apoptosis. These results suggest that both caspases and serine proteases are essential for A3D8-induced apoptosis.
A3D8 induces apoptosis in ATRA-resistant NB4 cells and in primary APL blasts
To determine whether the anti-CD44 mAb A3D8 could be a novel therapeutic agent for inducing apoptosis in APL, we examined whether it can induce apoptosis in NB4-LR2 cells that are resistant to ATRA and in primary blasts from APL patients. As shown in Figure 6a , treatment with A3D8 inhibited cell proliferation and induced a time-and dose-dependent apoptosis in NB4-LR2 cells. These results indicate that the apoptotic effect of A3D8 in NB4 cells is independent of their sensitivity to retinoic acid. Besides, treatment of freshly isolated blasts from two APL patients with A3D8 for 3 days induced ex vivo apoptotic cell death and caspase-3 activation detected at day 3 ( Figure 6b ). As described previously, 14 this apoptosis was preceded by an increased expression of myeloid differentiation antigens CD11b and CD15 at day 2 (data not shown). Interestingly, As 2 O 3 at 1.5 mM was unable to provoke apoptotic effect on blasts from both patients during a similar 3-day treatment.
Discussion
Induction of both differentiation and apoptosis is a new and promising approach to cancer therapy, well illustrated by the successful treatment of APL combining ATRA and arsenic compounds. However, the emergence of ATRA resistance and toxic side effects of As 2 O 3 have prompted the identification of new therapeutic agents. We have recently reported that the anti-CD44 mAb, A3D8, induces incomplete differentiation and substantial apoptotic cell death in APL NB4 cells. 11 Here, we show that several apoptosis-typical features were evidenced during the treatment of NB4 cells with A3D8, including PS externalization, alterations of mitochondrial membrane permeability (loss of DC m and release of cytochrome c) and DNA 
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Figure 4
Effect of neutralizing antibodies to the death receptors on A3D8-induced apoptosis. NB4 cells were exposed to IgG1 (control) or to A3D8 (2 mg/ml) for 3 days in the absence or the presence of either anti-TNF-R1 mAb (20 mg/ml), ZB4 anti-Fas mAb (20 mg/ml), anti-TRAIL-R1 (20 mg/ml) or anti-TRAIL-R2 (20 mg/ml) mAb. As a control, TNFa (250 ng/ml) was applied in the presence or absence of anti-TNF-R1 mAb. The percentage of apoptotic cells was measured by EB and AO staining. Data represent the mean7s.d. of triplicate cultures. Table 1 List of inhibitors and range of concentrations tested to block A3D8-induced apoptosis in NB4 cells 
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In agreement with our previously published work, 11 apoptosis is not an early consequence of CD44 ligation since these changes were clearly observed only at day 3 after the initial and incomplete differentiation process. However, it remains unknown why NB4 cells were more sensitive to CD44-mediated apoptosis than other leukemic myeloid cells like HL60 and THP-1 cells, which developed a moderate and late apoptosis after differentiation process at day 5 or 6.
11
Caspases, a class of cysteine proteases, are considered as the executioners in most apoptotic processes by cleaving major cellular proteins. 21, 22 Effector caspase-3 and -7 can be activated by initiator caspase-8 and -9, which are known to participate in distinct signalling pathways. Caspase-8 is usually activated by death receptors (extrinsic apoptotic pathway), whereas the intrinsic mitochondrial apoptotic pathway leads to the release of mitochondrial cytochrome c, which binding to Apaf-1 activates caspase-9 via apoptosome. We show that initiator caspase-8 and -9 and effector caspase-3 and -7 are concomitantly activated at day 3 after treatment with A3D8. However, by using specific caspase inhibitors, we demonstrated that only effector caspase-3/7 and initiator caspase-8 are involved in the apoptotic process induced by A3D8. As caspase-8 is believed to act upstream of mitochondria, this result is in good agreement with the observation that, in A3D8-treated NB4 cells, the caspase-8 inhibitor Z-IETD-fmk strongly decreased mitochondrial alterations (loss of DC m and cytochrome c release). Altogether, our results suggest that caspase-8 plays a primary role in the initiation of A3D8-induced apoptosis. Interestingly, caspase-8 activation is also associated with both As 2 O 3 -and ATRA-induced apoptosis in NB4 cells, 23, 28 pointing out some similarities between As 2 O 3 and ATRA-induced apoptotic pathways and the one induced by CD44 ligation with A3D8. In contrast, activation of cytochrome c/caspase-9 cascade may be considered as a secondary event in A3D8-induced apoptosis. Furthermore, caspase-9 pathway does not appear to be required in A3D8-mediated apoptosis since the caspase-9 inhibitor Z-LEHD-fmk did not exert protective effect against death. However, this does not exclude that other mitochondriamediated pathways might be involved in A3D8-induced apoptosis.
Several types of death receptors have been shown to activate caspase-8, including Fas, TNF receptor-R1, and TRAIL-R1 and -R2 receptors. In the context of NB4 cells, it has been clearly established that ATRA activates caspase-8 through the paracrine action of TRAIL. 28 On the contrary, there is no evidence that caspase-8 activation in As 2 O 3 -induced apoptosis of NB4 cells depends on death receptors and, in particular, it has been shown to be Fas independent. 23 Since the cell surface CD44 lacks death domains, we investigated whether CD44-induced apoptosis involved a death receptor signalling. Here, by using neutralizing antibodies to Fas, TNF-R1, and TRAIL-R1 and -R2, we failed to detect any involvement of death receptors in A3D8-induced apoptosis of NB4 cells. However, we cannot exclude a possible involvement of the Fas-associated death domain protein, the main adaptor for transmitting the death receptor signal, or of an autoprocessing of caspase-8 as described in drug-induced apoptosis. 29, 30 These various possibilities remain to be investigated in the context of A3D8-induced apoptosis of NB4 cells.
Although caspases are essential, they are not the only proteases involved in A3D8-induced apoptosis of NB4 cells since caspase inhibitors, including the pancaspase Z-VAD-fmk used at high concentrations, failed to fully inhibit the process of apoptosis. In this regard, A3D8-induced apoptosis in NB4 cells differed from apoptosis observed in these cells treated with other inducers such as arsenic, 31 CD437 32 and dithizone, 33 which was blocked by Z-VAD-fmk. However, a recent study shows that As 2 O 3 can trigger a caspase-independent necrotic cell death in several cells including NB4 cells. 34 There exits body evidence that proteases other than caspases may mediate or regulate apoptosis, while their precise nature seems to depend CD44-induced apoptosis in APL E Maquarre et al on the cell type and on the specific apoptosis inducer. 26, 27 In the present work, despite activation of calpain in A3D8-treated NB4 cells (data not shown), three calpain inhibitors were unable to inhibit A3D8-induced apoptosis (Table 1) . In contrast, the general serine protease inhibitor AEBSF significantly reduced A3D8-induced apoptosis and, when combined with Z-VADfmk, clearly displayed an additive effect resulting in complete inhibition of cell death. These results indicate that A3D8 is able to trigger in NB4 cells two distinct apoptotic pathways, one dependent on caspases and another involving serine proteases. Recent studies support a function for serine proteases in caspase-dependent or -independent apoptotic pathways. 35, 36 Whether serine proteases are involved upstream or downstream of caspase activation, or alternatively act in parallel pathways in A3D8-induced apoptosis, remains to be determined. Although the nature of serine protease involved in A3D8-induced apoptosis of NB4 cells is still not characterized, we hypothesize that it is a trypsin-like protease since A3D8-induced apoptosis was inhibited by TLCK, a trypsin-like serine protease inhibitor, but not by TPCK, a chymotrypsin-like serine protease inhibitor. A possible candidate is the mitochondrial serine protease Omi/ HtrA2 because it displays a trypsin-like activity and can initiate caspase-dependent and -independent cell death. 37 In conclusion, our results show that the ligation of CD44 with A3D8 mAb induces apoptosis in NB4 cells, through a mechanism involving a caspase-dependent pathway and a serine protease-dependent pathway. This feature distinguish CD44-induced apoptosis from the ones induced by ATRA or As 2 O 3 , and might account, at least in part, for the capacity of A3D8 to induce apoptosis of APL cells in which ATRA and As 2 O 3 were inefficient (ie the ATRA-resistant NB4-LR2 cells and As 2 O 3 -resistant primary APL blasts). Thus, ligation with anti-CD44 A3D8 mAb might provide a new alternative treatment of ATRA-or As 2 O 3 -resistant APL.
